Literature DB >> 33188453

Fetal cardiomyocyte phenotype, ketone body metabolism, and mitochondrial dysfunction in the pathology of atrial fibrillation.

Sean M Brown1, Nicholas K Larsen1, Finosh G Thankam2, Devendra K Agrawal3.   

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia diagnosed in clinical practice. Even though hypertension, congestive heart failure, pulmonary disease, and coronary artery disease are the potential risk factors for AF, the underlying molecular pathology is largely unknown. The reversion of the mature cardiomyocytes to fetal phenotype, impaired ketone body metabolism, mitochondrial dysfunction, and the cellular effect of reactive oxygen species (ROS) are the major underlying biochemical events associated with the molecular pathology of AF. On this background, the present manuscript sheds light into these biochemical events in regard to the metabolic derangements in cardiomyocyte leading to AF, especially with respect to structural, contractile, and electrophysiological properties. In addition, the article critically reviews the current understanding, potential demerits, and translational strategies in the management of AF.

Entities:  

Keywords:  Arrhythmias; Atrial fibrillation; Cardiac metabolism; Cardiomyocyte; Cardiomyocyte metabolism

Mesh:

Substances:

Year:  2020        PMID: 33188453      PMCID: PMC7878362          DOI: 10.1007/s11010-020-03980-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  118 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 3.  Recent advances in the molecular pathophysiology of atrial fibrillation.

Authors:  Reza Wakili; Niels Voigt; Stefan Kääb; Dobromir Dobrev; Stanley Nattel
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

Review 5.  Management of paroxysmal atrial fibrillation.

Authors:  G Y Lip; M J Metcalfe; A P Rae
Journal:  Q J Med       Date:  1993-08

6.  Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.

Authors:  D L Disch; M L Greenberg; P T Holzberger; D J Malenka; J D Birkmeyer
Journal:  Ann Intern Med       Date:  1994-03-15       Impact factor: 25.391

7.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

8.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

Review 9.  Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses.

Authors:  Hugh Calkins; Matthew R Reynolds; Peter Spector; Manu Sondhi; Yingxin Xu; Amber Martin; Catherine J Williams; Isabella Sledge
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-06-02

Review 10.  Early management of atrial fibrillation to prevent cardiovascular complications.

Authors:  Stanley Nattel; Eduard Guasch; Irina Savelieva; Francisco G Cosio; Irene Valverde; Jonathan L Halperin; Jennifer M Conroy; Sana M Al-Khatib; Paul L Hess; Paulus Kirchhof; Joseph De Bono; Gregory Y H Lip; Amitava Banerjee; Jeremy Ruskin; Dan Blendea; A John Camm
Journal:  Eur Heart J       Date:  2014-02-16       Impact factor: 29.983

View more
  1 in total

1.  Post-Operative Atrial Fibrillation: Current Treatments and Etiologies for a Persistent Surgical Complication.

Authors:  Leilani A Lopes; Devendra K Agrawal
Journal:  J Surg Res (Houst)       Date:  2022-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.